drugset / Trial / NCT01594515

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers

NCT01594515

Phase 1 Completed 70 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

In this first-in-man trial, safety, tolerability, pharmacokinetics, and selected pharmacodynamics parameters of BI 1015550 will be assessed in healthy male volunteers.

Timeline

Start
2012-05
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerandomilast Small molecule Oral

Indications

No indication recorded.